高雄市立岡山醫院（委託秀傳醫療社團法人經營）

吳登強

高雄醫學大學附設中和紀念醫院胃腸內科

The gut microbiota exists in a symbiotic relationship with its host, playing a decisive role in the host's nutrition, immunity and metabolism. Accumulating studies have revealed the associations between gut dysbiosis or some special bacteria and various cancers. Emerging data suggest that changing gut microbiota can modulate cancer patients' therapeutic responses to chemotherapy, radiotherapy and immunotherapy, including clinical efficacy and sensitivity to toxicity. The most dramatic manipulation of gut microbiota refers to fecal microbiota transplantation (FMT). FMT was associated with favorable changes in immune cell infiltrates and gene expression profiles in both the gut lamina propria and the tumor microenvironment. Some specific pathogens have been identified from colorectal and pancreatic cancer patients’ stool, and FMT presented some kinds of therapeutic effects in associated animal models, which revealed that microbiota-based treatment might be useful to manage these malignant diseases. Some case reports and series revealed the potential of FMT in alleviating various cancers linked to intestinal dysbiosis and cancer treatment-associated complications. Additionally, FMT could enhance the efficacy of cancer immunotherapy, thus remarkably affect clinical outcomes. However, FMT has not been clearly studied in cancer management and large-sample randomized controlled studies are urgently required to delineate the validity of FMT, especially focus on the long-term consequences. With the rapid progress of gut microbiology, FMT might become a promising therapeutic strategy for cancers in the near future.

醫事人員執業，應接受下列課程之繼續教育：
A專業課程
B專業品質
C專業倫理
D專業相關法規
A+ B+C+D合計一百二十點，其中B+C+D 至少十二點（應包括感染管制及性別議題之課程）；超過二十四點者，以二十四點計 

 

KaoHsiung Kcma
社團法人高雄縣醫師公會